Short-courses of dexamethasone abolish bisphosphonate-induced reductions in bone toughness

Tianyi D. Luo, Matthew Allen

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Atypical femoral fractures, which display characteristics of brittle material failure, have been associated with potent remodeling suppression drugs. Given the millions of individuals treated with this class of drugs it is likely that other factors play a role in these fractures. Some evidence suggests that concomitant use of corticosteroids may contribute to the pathogenesis although data in this area is lacking. The goal of this study was to assess the combined role of bisphosphonates and dexamethasone on bone mechanical properties. Skeletally mature beagle dogs were either untreated controls, or treated with zoledronic acid (ZOL), dexamethasone (DEX), or ZOL. +. DEX. Zoledronic acid (0.06. mg/kg) was given monthly via IV infusion for 9. months. DEX (5. mg) was administered daily for one week during each of the last three months of the 9. month experiment. Ribs were harvested and assessed for bone geometry, mechanical properties, and remodeling rate (n. = 3-6 specimens per group). DEX significantly suppressed intracortical remodeling compared to vehicle controls while both ZOL and the combination of DEX. +. ZOL nearly abolished intracortical remodeling. ZOL treatment resulted in significantly lower bone toughness, determined from 3-point bending tests, compared to all other treatment groups while the toughness in ZOL. +. DEX animals was identical to those of untreated controls. These findings suggest that short-courses of dexamethasone not only do not adversely affect toughness in the setting of bisphosphonates, but also actually reverse the adverse effects of its treatment. Understanding the mechanism for this tissue-level effect could lead to novel approaches for reducing the risk of atypical femoral fractures.

Original languageEnglish
Pages (from-to)199-203
Number of pages5
JournalBone
Volume56
Issue number1
DOIs
StatePublished - Sep 2013

Fingerprint

zoledronic acid
Diphosphonates
Dexamethasone
Bone and Bones
Femoral Fractures
Ribs
Pharmaceutical Preparations

Keywords

  • Mechanical properties
  • Remodeling suppression
  • Toughness
  • Zoledronic acid

ASJC Scopus subject areas

  • Physiology
  • Endocrinology, Diabetes and Metabolism
  • Histology

Cite this

Short-courses of dexamethasone abolish bisphosphonate-induced reductions in bone toughness. / Luo, Tianyi D.; Allen, Matthew.

In: Bone, Vol. 56, No. 1, 09.2013, p. 199-203.

Research output: Contribution to journalArticle

@article{3a80574e9e1948759d9e9d6f6acfab2c,
title = "Short-courses of dexamethasone abolish bisphosphonate-induced reductions in bone toughness",
abstract = "Atypical femoral fractures, which display characteristics of brittle material failure, have been associated with potent remodeling suppression drugs. Given the millions of individuals treated with this class of drugs it is likely that other factors play a role in these fractures. Some evidence suggests that concomitant use of corticosteroids may contribute to the pathogenesis although data in this area is lacking. The goal of this study was to assess the combined role of bisphosphonates and dexamethasone on bone mechanical properties. Skeletally mature beagle dogs were either untreated controls, or treated with zoledronic acid (ZOL), dexamethasone (DEX), or ZOL. +. DEX. Zoledronic acid (0.06. mg/kg) was given monthly via IV infusion for 9. months. DEX (5. mg) was administered daily for one week during each of the last three months of the 9. month experiment. Ribs were harvested and assessed for bone geometry, mechanical properties, and remodeling rate (n. = 3-6 specimens per group). DEX significantly suppressed intracortical remodeling compared to vehicle controls while both ZOL and the combination of DEX. +. ZOL nearly abolished intracortical remodeling. ZOL treatment resulted in significantly lower bone toughness, determined from 3-point bending tests, compared to all other treatment groups while the toughness in ZOL. +. DEX animals was identical to those of untreated controls. These findings suggest that short-courses of dexamethasone not only do not adversely affect toughness in the setting of bisphosphonates, but also actually reverse the adverse effects of its treatment. Understanding the mechanism for this tissue-level effect could lead to novel approaches for reducing the risk of atypical femoral fractures.",
keywords = "Mechanical properties, Remodeling suppression, Toughness, Zoledronic acid",
author = "Luo, {Tianyi D.} and Matthew Allen",
year = "2013",
month = "9",
doi = "10.1016/j.bone.2013.06.004",
language = "English",
volume = "56",
pages = "199--203",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Short-courses of dexamethasone abolish bisphosphonate-induced reductions in bone toughness

AU - Luo, Tianyi D.

AU - Allen, Matthew

PY - 2013/9

Y1 - 2013/9

N2 - Atypical femoral fractures, which display characteristics of brittle material failure, have been associated with potent remodeling suppression drugs. Given the millions of individuals treated with this class of drugs it is likely that other factors play a role in these fractures. Some evidence suggests that concomitant use of corticosteroids may contribute to the pathogenesis although data in this area is lacking. The goal of this study was to assess the combined role of bisphosphonates and dexamethasone on bone mechanical properties. Skeletally mature beagle dogs were either untreated controls, or treated with zoledronic acid (ZOL), dexamethasone (DEX), or ZOL. +. DEX. Zoledronic acid (0.06. mg/kg) was given monthly via IV infusion for 9. months. DEX (5. mg) was administered daily for one week during each of the last three months of the 9. month experiment. Ribs were harvested and assessed for bone geometry, mechanical properties, and remodeling rate (n. = 3-6 specimens per group). DEX significantly suppressed intracortical remodeling compared to vehicle controls while both ZOL and the combination of DEX. +. ZOL nearly abolished intracortical remodeling. ZOL treatment resulted in significantly lower bone toughness, determined from 3-point bending tests, compared to all other treatment groups while the toughness in ZOL. +. DEX animals was identical to those of untreated controls. These findings suggest that short-courses of dexamethasone not only do not adversely affect toughness in the setting of bisphosphonates, but also actually reverse the adverse effects of its treatment. Understanding the mechanism for this tissue-level effect could lead to novel approaches for reducing the risk of atypical femoral fractures.

AB - Atypical femoral fractures, which display characteristics of brittle material failure, have been associated with potent remodeling suppression drugs. Given the millions of individuals treated with this class of drugs it is likely that other factors play a role in these fractures. Some evidence suggests that concomitant use of corticosteroids may contribute to the pathogenesis although data in this area is lacking. The goal of this study was to assess the combined role of bisphosphonates and dexamethasone on bone mechanical properties. Skeletally mature beagle dogs were either untreated controls, or treated with zoledronic acid (ZOL), dexamethasone (DEX), or ZOL. +. DEX. Zoledronic acid (0.06. mg/kg) was given monthly via IV infusion for 9. months. DEX (5. mg) was administered daily for one week during each of the last three months of the 9. month experiment. Ribs were harvested and assessed for bone geometry, mechanical properties, and remodeling rate (n. = 3-6 specimens per group). DEX significantly suppressed intracortical remodeling compared to vehicle controls while both ZOL and the combination of DEX. +. ZOL nearly abolished intracortical remodeling. ZOL treatment resulted in significantly lower bone toughness, determined from 3-point bending tests, compared to all other treatment groups while the toughness in ZOL. +. DEX animals was identical to those of untreated controls. These findings suggest that short-courses of dexamethasone not only do not adversely affect toughness in the setting of bisphosphonates, but also actually reverse the adverse effects of its treatment. Understanding the mechanism for this tissue-level effect could lead to novel approaches for reducing the risk of atypical femoral fractures.

KW - Mechanical properties

KW - Remodeling suppression

KW - Toughness

KW - Zoledronic acid

UR - http://www.scopus.com/inward/record.url?scp=84880177498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880177498&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2013.06.004

DO - 10.1016/j.bone.2013.06.004

M3 - Article

C2 - 23774445

AN - SCOPUS:84880177498

VL - 56

SP - 199

EP - 203

JO - Bone

JF - Bone

SN - 8756-3282

IS - 1

ER -